1061 related articles for article (PubMed ID: 27752710)
1. Empagliflozin decreases myocardial cytoplasmic Na
Baartscheer A; Schumacher CA; Wüst RC; Fiolet JW; Stienen GJ; Coronel R; Zuurbier CJ
Diabetologia; 2017 Mar; 60(3):568-573. PubMed ID: 27752710
[TBL] [Abstract][Full Text] [Related]
2. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats.
Lee TI; Chen YC; Lin YK; Chung CC; Lu YY; Kao YH; Chen YJ
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987285
[TBL] [Abstract][Full Text] [Related]
4. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na
Uthman L; Li X; Baartscheer A; Schumacher CA; Baumgart P; Hermanides J; Preckel B; Hollmann MW; Coronel R; Zuurbier CJ; Weber NC
Biomed Pharmacother; 2022 Feb; 146():112515. PubMed ID: 34896968
[TBL] [Abstract][Full Text] [Related]
6. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
[TBL] [Abstract][Full Text] [Related]
7. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Packer M; Anker SD; Butler J; Filippatos G; Zannad F
JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
[TBL] [Abstract][Full Text] [Related]
8. Chronic inhibition of na(+)/h(+)-exchanger in the heart.
Baartscheer A
Curr Vasc Pharmacol; 2006 Jan; 4(1):23-9. PubMed ID: 16472174
[TBL] [Abstract][Full Text] [Related]
9. Modification of intracellular calcium concentration in cardiomyocytes by inhibition of sarcolemmal Na+/H+ exchanger.
Saini HK; Dhalla NS
Am J Physiol Heart Circ Physiol; 2006 Dec; 291(6):H2790-800. PubMed ID: 16861694
[TBL] [Abstract][Full Text] [Related]
10. Na+/H+ exchanger inhibitor cariporide attenuates the mitochondrial Ca2+ overload and PTP opening.
Toda T; Kadono T; Hoshiai M; Eguchi Y; Nakazawa S; Nakazawa H; Higashijima N; Ishida H
Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3517-23. PubMed ID: 17906113
[TBL] [Abstract][Full Text] [Related]
11. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.
Luconi M; Raimondi L; Di Franco A; Mannucci E
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1071-1078. PubMed ID: 27776917
[TBL] [Abstract][Full Text] [Related]
12. Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model.
Baartscheer A; Schumacher CA; van Borren MM; Belterman CN; Coronel R; Fiolet JW
Cardiovasc Res; 2003 Mar; 57(4):1015-24. PubMed ID: 12650879
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE/PKC/NOX axis.
Li X; Wang M; Kalina JO; Preckel B; Hollmann MW; Albrecht M; Zuurbier CJ; Weber NC
Redox Biol; 2024 Feb; 69():102979. PubMed ID: 38061206
[TBL] [Abstract][Full Text] [Related]
14. EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV; Chilton R
Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
[TBL] [Abstract][Full Text] [Related]
15. Sodium-Hydrogen Exchanger Isoform-1 Inhibition: A Promising Pharmacological Intervention for Resuscitation from Cardiac Arrest.
Gazmuri RJ; Radhakrishnan J; Ayoub IM
Molecules; 2019 May; 24(9):. PubMed ID: 31067690
[TBL] [Abstract][Full Text] [Related]
16. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
Spigoni V; Fantuzzi F; Carubbi C; Pozzi G; Masselli E; Gobbi G; Solini A; Bonadonna RC; Dei Cas A
Cardiovasc Diabetol; 2020 Apr; 19(1):46. PubMed ID: 32264868
[TBL] [Abstract][Full Text] [Related]
18. EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV; Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S53-S58. PubMed ID: 28606345
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin treatment rescues abnormally reduced Na
Sauer J; Marksteiner J; Lilliu E; Hackl B; Todt H; Kubista H; Dostal C; Podesser BK; Kiss A; Koenig X; Hilber K
Am J Physiol Heart Circ Physiol; 2024 Feb; 326(2):H418-H425. PubMed ID: 38099845
[TBL] [Abstract][Full Text] [Related]
20. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
Scheen AJ
Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
